I2O

i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules

Retrieved on: 
Thursday, January 6, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Harvard University, Therapy, Johnson & Johnson, Inflammation, Research, Patient, Lists of diseases, ILS, Janssen Pharmaceuticals, GI, Adoption, Ionic liquid, Human, Peptide, Sanofi, Janssen, Pharmaceutical industry, I2O

i2O Therapeutics , a developer of oral biologic products based on its proprietary ionic liquid platform, today announced a collaboration and option agreement with Janssen Biotech, Inc., for Janssen Research & Development to evaluate the use of ionic liquid technology for the oral delivery of macromolecules.

Key Points: 
  • i2O Therapeutics , a developer of oral biologic products based on its proprietary ionic liquid platform, today announced a collaboration and option agreement with Janssen Biotech, Inc., for Janssen Research & Development to evaluate the use of ionic liquid technology for the oral delivery of macromolecules.
  • This research collaboration underscores i2Os mission to apply its Ionic Liquid platform towards the oral delivery of diverse payloads that can enable the wider adoption of much needed therapies for patients.
  • We look forward to working collaboratively with Janssen to investigate the oral bioavailability of macromolecules using ionic liquids.
  • In 2021, i2O announced a collaboration with Sanofi to enable the oral delivery of nanobody-based medicines across a broad range of therapeutic areas.

Global Smart Water Management Market Report 2021: Growth, Trends, Impact of COVID-19, and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021
Other Natural Resources, Natural Resources, Traction, Solution, SCADA, Schneider Electric, Population, Urbanization, IOT, AWWA, COVID-19, Acquisition, Adoption, Open Systems International, Argus – Audit Record Generation and Utilization System, Hitachi, CAGR, M2M, Risk, SUEZ, Water, Attention, Suez, GIS, Esri, Efficiency, IBM, Software, OSI, Coronavirus, UN, Industry, AMI, Policy, AMWA, Maintenance, UN World Water Development Report, Ageing, Partnership, Technology, Honeywell, Communication, Animal, Agriculture, Renewable energy, SensUs, Growth, I2O

The "Global Smart Water Management Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Smart Water Management Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Smart Water Management Market is expected to register a CAGR of approximately 12.5% over the forecast period (2021-2026).
  • have transformed water management systems to address the challenges faced by water utilities, residents, and industries erroneous billing and water management.
  • The smart water management market is quite fragmented as the market comprises several global players and emerging new players vying for attention in a fairly contested market space.

i2O Therapeutics Announces Research Collaboration with Sanofi to Enable Oral Delivery of Nanobody-based Medicines

Retrieved on: 
Wednesday, February 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Companies, CAC 40, Sanofi, JDRF, I2O, i2O Therapeutics, Sanofi

i2O Therapeutics , developers of a platform for oral delivery of traditionally injectable biological drugs, announced today a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody-based medicines, which are currently administered through intravenous or subcutaneous injections.

Key Points: 
  • i2O Therapeutics , developers of a platform for oral delivery of traditionally injectable biological drugs, announced today a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody-based medicines, which are currently administered through intravenous or subcutaneous injections.
  • The research collaboration between i2O Therapeutics and Sanofi will explore a new oral route of administering nanobodies.
  • Our mission at i2O Therapeutics is to develop safe and effective oral formulations of therapies traditionally limited to injections and we are excited to partner with Sanofi to advance this mission, said Ravi Srinivasan, co-founder and director of i2O Therapeutics.
  • i2O Therapeutics announced seed funding in April 2020, which was led by Sanofi Ventures, the corporate venture capital arm of Sanofi, and JDRF T1D Fund.

i2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon

Retrieved on: 
Thursday, December 3, 2020
Biotechnology, Medical devices, Other Health, Health, Pharmaceutical, I2O, Input/output, i2O Therapeutics, Colorcon Ventures

i2O Therapeutics , an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures , the corporate venture fund of Colorcon Inc.

Key Points: 
  • i2O Therapeutics , an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures , the corporate venture fund of Colorcon Inc.
  • In addition to this investment, Colorcon will collaborate with i2O to accelerate i2Os research and development efforts.
  • We welcome Colorcon Ventures as a strategic investor at this pivotal time of company growth, said Ravi Srinivasan, Ph.D., Chief Executive Officer of i2O Therapeutics.
  • Colorcon Ventures strategic focus on technologies that transform conventional delivery pathways aligns well with i2O.